Incidence and prevalence of neuroendocrine tumor is steadily rising, mainly due Multiple endocrine neoplasia type 1 (MEN1), Multiple endocrine neoplasia type 2 (MEN2), Neurofibromatosis type 1 (NF1), Von Hippel-Lindau syndrome (VHL) and Tuberous sclerosis complex (TSC) disease in the U.S. Moreover, based on a study published in the JAMA Oncology Journal, survival rate for all neuroendocrine tumor treatment have improved, especially for distant-stage gastrointestinal neuroendocrine tumor treatment and pancreatic neuroendocrine tumor treatment. This is mainly attributed to improved outcomes of availability of better therapies and early diagnosis. Introduction of new therapies and extended indications for approved drugs would benefit the growth of neuroendocrine tumor treatment market in North America and in turn is expected to significantly fuel growth of the global market. U.S. is the largest market for NET, in terms of revenue. No specific data is available regarding incidence of neuroendocrine tumors in Canada. However, according to the Canadian Cancer Society, 315 people in Canada were diagnosed with endocrine cancers in 2012 and the rate is increasing with early diagnosis and stage migration.
North America neuroendocrine tumor treatment market is expected to dominate the global gastrointestinal NET segment throughout the forecast period. According to Coherent Market Insights analysis, various national universities and small scale pharma-company work on developing various NET drugs and modify clinical approach to treat neuroendocrine tumors. This gives pharma and biotech companies a major opportunity to market their products in the U.S.
The global neuroendocrine tumor treatment market was valued at US$ 1,197.3 million in 2015 and is expected to witness a CAGR of 10.5% during the forecast period (2017 – 2025).
Innovate drug in pharmaceutical company product pipeline to boost the Neuroendocrine Tumor Treatment Market
There are various medical treatment to treat cancer, and targeted therapy is one of the most preferred to treat neuroendocrine tumor treatment. Targeted therapy is a futuristic and highly effective approach for treating cancers and hence, targeted NET therapies are projected to gain significant demand in the near future. Though somatostatins are effective in treating some types of pituitary tumors, regulatory approval for NET is expected to further encourage its research as a combination therapy with targeted drugs. Pasireotide is another somatostatin analogue under study for treating NET. Somatostain analogs are the preferred therapy for chronic control and are effective for long-term management. Also, Avastin (Bevacizumab), a monoclonal antibody, is being studied for its efficacy in treating carcinoid tumors. Netazepide, gastrin/CCK2 receptor antagonist, is found to shrink tumors in patients having carcinoid tumors of the stomach and high gastrin levels. Being a rare disease, regulatory agencies are providing fast-track and orphan drug status to the potential drug candidates.
Imaging technique is one of the useful tools for assessing key tumor which in turn will boost growth of the neuroendocrine tumor treatment market
There are various other types of neuroendocrine tumors that may occur across various parts of the body and have different growth patterns. The other neuroendocrine tumors include thymus, thyroid gland, adrenal gland and pituitary gland. These neuroendocrine cells multiply at a very slow pace as compared to a regular neuroendocrine cells of GI, Lungs, and Pancreases. These seldom cause symptoms at an early diseases stage, however, when these symptoms are identified they are sometimes misdiagnosed as any other lump. It is highly important to identify the other neuroendocrine tumors, as if left undiagnosed, condition may lead to malignant tumor. Proper treatment planning is necessary as Neuroendocrine Tumor Treatment that can otherwise be contained in a particular area of the body, may spread to nearby tissues or lymph nodes and may eventually spread throughout the body. There are limited treatment options for pancreatic neuroendocrine tumors. One of the most significant and common treatment is surgical removal of tumors.